Vascular Solutions downgraded to Hold from Buy at Benchmark Co. Benchmark Co. downgraded Vascular Solutions citing valuation following the company's Q4 results. The firm keeps a $17 price target for shares.
News For VASC From The Last 14 Days
Check below for free stories on VASC the last two weeks.